However, methodologically sound evaluation is required to test the status quo.
The HEALTH trial found that at 15 months after randomisation, women allocated laparoscopic supracervical hysterectomy were more satisfied with their treatment ( The real-world implications and worldwide generalisability of this study are where we must now turn our attention. Although this trial specifically examined laparoscopic supracervical hysterectomy, contemporary evidence is lacking with respect to the efficacy and safety of cervix preservation versus removal for heavy menstrual bleeding. 4 In particular, cervical conservation raises issues of specimen removal, need for cervical screening, and the potential for new or ongoing symptoms secondary to the retained cervical stump. Within a month of recruitment to the HEALTH study, the US Food and Drug Administration issued a safety warning (April 17, 2014) on the use of power morcellation, which was standard in this study, because of a risk of inadvertent spread of undiagnosed malignancy. 5 This concern is shared by many international committees including the European Society of Gynaecological Oncology, which states that total hysterectomy with en bloc resection is preferred over laparoscopic supracervical hysterectomy. 6 Consequently, numbers of laparoscopic supracervical hysterectomies have decreased. 7 The long-term potential for reoperation (estimated at up to 20%, secondary to issues related to the cervical stump 8, 9 ) is not addressed by this study 2 as longer follow-up of patients would be necessary. Therefore, clinicians might want to await the authors' own ongoing evaluation of total laparoscopic hysterectomy versus laparoscopic supracervical hysterectomy to further determine safety and outcomes of the two approaches. 2 Although the standard of care provided by the study sites represents real-world experience at the time of study recruitment, we must be cognisant that these standards continue to evolve, thereby shifting the riskto-benefit ratio for each procedure. Same day discharge is feasible within hours, even after complex total laparoscopic hysterectomy, 10 and second-generation ablation can be offered with minimal pain medication in an ambulatory setting (outside the operating room and without general anaesthetic) safely and with even earlier discharge. 3, 11, 12 Hospital discharge, hospital stay, and general anaesthetic administration might affect patient decisions and short-term experience.
We recognise that a randomised trial is the gold standard of evidence-based practice; however, patients who enrol in such trials eliminate their personal preference in the decision-making process, which is often an important factor in real-world practice. A patient empowered with appropriate counselling and autonomy in the decision-making process is less likely to regret the decision, even if the option selected leads to additional intervention in the future. For example, many of our patients might select endometrial ablation in a setting without a general anaesthetic, minimal recovery, and almost no postoperative pain while acknowledging that there remains a 20% chance of hysterectomy in their future.
The completion of a successful multicentre randomised trial of this size in benign surgical gynaecology should be acknowledged. Although heavy menstrual bleeding is common, alternative treatments, particularly surgical treatments, are under-evaluated in randomised trials. Clinicians often reserve surgical management and hysterectomy for patients after they have tried medical therapy. The HEALTH trial highlights that surgical management for heavy menstrual bleeding (both laparoscopic supracervical hysterectomy and endometrial ablation) is safe, effective, and leads to high patient satisfaction. 2 Although this study alone will not completely change practice because of the complexities mentioned in this Comment, it will offer another set of data to help counsel patients, aiding delivery of evidence-based, patient-centred care for women with heavy menstrual bleeding.
